Book-to-bill ratio still high
The book-to-bill ratio for North American-based semiconductor equipment manufacturers, such as Applied Materials Inc, climbed to 1.09 last month — the highest level since May 2012, industry association SEMI said yesterday. That marked the ninth consecutive month that the ratio has been above one. A book-to-bill ratio greater than one indicates growth for the industry. The three-month average of worldwide bookings in the sector rose 4.3 percent to US$1.47 billion last month from May’s US$1.41 billion, according to SEMI’s data. The three-month average of worldwide billings fell 4.8 percent to US$1.34 billion last month from US$1.41 billion in May.
OBI Pharma trials set
OBI Pharma Inc (台灣浩鼎) announced on Monday that it had met the goal of collecting 342 patients for the phase two and three clinical trials for OBI-822, a new drug for treating metastatic breast cancer. OBI Pharma chairman Michael Chang (張念慈) said the completion of the patient collection phase shows the OBI-822 project is progressing more smoothly than expected. The company is to analyze the data after the last patient completes the treatment stage, he said. The multinational clinical test is being conducted as a randomized control trial in which 45 medical centers across Taiwan, the US, South Korea, India and Hong Kong are participating, the company said.